James Hassard Net Worth

The estimated Net Worth of James Hassard is at least $2.91 Million dollars as of 5 July 2024. Mr Hassard owns over 15,000 units of Arrowhead Pharmaceuticals stock worth over $926,783 and over the last 4 years he sold ARWR stock worth over $1,495,298. In addition, he makes $488,296 as Chief Commercial Officer at Arrowhead Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr Hassard ARWR stock SEC Form 4 insiders trading

Mr has made over 4 trades of the Arrowhead Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of ARWR stock worth $295,950 on 5 July 2024.

The largest trade he's ever made was selling 15,625 units of Arrowhead Pharmaceuticals stock on 7 January 2021 worth over $1,171,875. On average, Mr trades about 6,156 units every 159 days since 2021. As of 5 July 2024 he still owns at least 44,259 units of Arrowhead Pharmaceuticals stock.

You can see the complete history of Mr Hassard stock trades at the bottom of the page.

Mr. James Hassard biography

James Hassard is the Chief Commercial Officer at Arrowhead Pharmaceuticals.

What is the salary of Mr Hassard?

As the Chief Commercial Officer of Arrowhead Pharmaceuticals, the total compensation of Mr Hassard at Arrowhead Pharmaceuticals is $488,296. There are 9 executives at Arrowhead Pharmaceuticals getting paid more, with Christopher Anzalone having the highest compensation of $2,216,260.

How old is Mr Hassard?

Mr Hassard is 53, he's been the Chief Commercial Officer of Arrowhead Pharmaceuticals since . There are 11 older and 5 younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals Inc. is Dr. Mark Seefeld, 67, who is the Head of Toxicology & VP.

What's Mr Hassard's mailing address?

James's mailing address filed with the SEC is C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO, CA, 92121.

Insiders trading at Arrowhead Pharmaceuticals

Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone, and Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.

What does Arrowhead Pharmaceuticals do?

arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing

Complete history of Mr Hassard stock trades at Arrowhead Pharmaceuticals and Crinetics Pharmaceuticals Inc

Arrowhead Pharmaceuticals executives and stock owners

Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include:

• Christopher Anzalone,
  President, Chief Executive Officer, Director
• Kenneth Myszkowski,
  Chief Financial Officer
• Dr. Christopher R. Anzalone,
  CEO, Pres & Director
• Patrick O'Brien,
  General Counsel
• Kenneth A. Myszkowski,
  Chief Financial Officer
• Dr. Javier San Martin M.D.,
  Chief Medical Officer
• Dr. Javier San Martin,
  Chief Medical Officer
• Douglass Given,
  Chairman of the Board
• Michael Perry,
  Lead Independent Director
• James Hassard,
  Chief Commercial Officer
• Dr. Bruce D. Given,
  Advisor
• William Waddill,
  Independent Director
• Mauro Ferrari,
  Independent Director
• Vincent Anzalone,
  IR Contact Officer
• Oye Olukotun,
  Independent Director
• Marianne De Backer,
  Independent Director
• Javier San Martin,
  Chief Medical Officer
• James Hassard,
  Chief Commercial Officer
• Curt Bradshaw,
  Chief Scientific Officer
• Dr. Mark Seefeld,
  Head of Toxicology & VP
• Dr. James C. Hamilton,
  Sr. VP of Discovery & Translational Medicine
• Patrick O'Brien,
  Chief Compliance Officer, Gen. Counsel & Corp. Sec.
• Howard Lovy,
  Director of Communications
• Jane Davidson,
  Head of HR & Admin., VP and Corp. Sec.
• Dr. Mark M. Davis,
  Founder and Founder & Director of Insert Therapeutics Inc & Calando
• Bruce D Given,
  Chief Operating Officer
• Edward W Frykman,
  Director
• David M Knott,
  10% owner
• Douglas B Given,
  Director
• David L. Lewis,
  Chief Scientific Officer
• Joseph Theodore Iii Kingsley,
  Chief Financial Officer
• Zhen Li,
  Snr. VP, Chem and Non-Clin Dev
• Peter Brian Leone,
  VP, Strategy & Program Mgmt
• Victoria Vakiener,
  Director
• Leon Ekchian,
  President
• Marshall Robert Ching,
  10% owner
• James M Jr Phillips,
  Secretary
• Charles Mc Kenney,
  Director
• R Bruce Stewart,
  President
• Leroy T Rahn,
  Director
• Paul Clayton Mc Donnel,
  Chief Financial Officer
• James C Hamilton,
  Chief Discovery/Trans Medicine
• Hongbo Lu,
  Director
• Tracie Oliver,
  Chief Commercial Officer